Table 2.
Summary of the results of the studies included in the systematic review on the role of microRNA in breast cancer diagnosis.
First Author, Year | Specimen Source | MiR | Direction | Cut_Off (ng/mL) |
AUC | Sens | Spec | Fold Change |
---|---|---|---|---|---|---|---|---|
Zhu W, 2009 [13] | Serum | 16 | Up | |||||
145 | Up | |||||||
155 | Down | |||||||
Heneghan H, 2010 [14] | Blood | 21 | Up | |||||
145 | Up | |||||||
155 | Up | |||||||
195 | Up | 0.94 (0.91–0.97) |
87.70 | 91.00 | 25.00 | |||
10b | Down | |||||||
Let-7a | Up | |||||||
Roth C, 2010 [15] | Serum | 141 | ||||||
155 | Up | 1.60 | ||||||
10b | ||||||||
34a | ||||||||
Wang F, 2010 [16] | Serum | 21 | Up | 2.50 | ||||
126 | Down | 2.00 | ||||||
155 | Up | 3.50 | ||||||
335 | Up | 2.00 | ||||||
106a | Up | 1.90 | ||||||
199a | Down | 2.00 | ||||||
Asaga S, 2011 [17] | Serum | 21 | Up | 3.30 | 0.72 | 75.00 | 67.00 | |
Guo LJ, 2012 [18] | Serum | 181a | Down | 0.74 | 0.67 (0.60–0.74) |
70.70 | 59.90 | 0.36 |
Schrauder MG, 2012 [19] | Serum | 202 | Up | 0.68 | 19.38 | |||
718 | Down | 0.77 | 5.44 | |||||
Schwarzenbach H, 2012 [20] | Serum | 21 | 0.85 (0.78–0.91) |
|||||
214 | 0.92 (0.88–0.97) |
|||||||
19a | ||||||||
20a | 0.68 (0.59–0.77) |
|||||||
Sun Y, 2012 [21] | Serum | 155 | Up | 1.91 | 0.80 (0.65–0.82) |
65.00 | 81.80 | 2.94 |
van Schooneveld E, 2012 [22] | Serum | 215 | Up | |||||
299 | Down | |||||||
411 | Down | |||||||
452 | Down | |||||||
Wu Q, 2012 [23] | Serum | 222 | Up | 0.01 | 0.67 (0.57–0.78) |
74.00 | 60.00 | |
Zhao FL, 2012 [24] | Serum | 10b | Up | |||||
Chan M, 2013 [25] | Serum | 1 | Up | 2.67 | ||||
133a | Up | 2.62 | ||||||
133b | Up | 2.41 | ||||||
92a | Up | 1.32 | ||||||
Cuk K, 2013 [26] | Plasma | 409 | Up | 0.66 (0.59–0.74) |
||||
801 | Up | 0.64 (0.56–0.72) |
||||||
148b | Up | 0.65 (0.58–0.73) |
||||||
376c | Up | 0.66 (0.59–0.74) |
||||||
Eichelser C, 2013 [27] | Serum | 17 | Down | 0.68 | 18.80 | 100.00 | ||
93 | Up | 0.70 | 44.90 | 100.00 | ||||
155 | Up | 0.78 | 70.60 | 42.70 | ||||
373 | Up | 0.88 | 76.60 | 100.00 | ||||
10b | Up | 21.80 | 92.10 | |||||
34a | Up | 0.64 | 59.80 | 76.00 | ||||
Godfrey AC, 2013 [28] | Serum | 222 | Down | |||||
181a | Up | |||||||
18a | Up | |||||||
Kumar S, 2013 [29] | Plasma | 21 | Up | |||||
146a | Up | |||||||
Ng EKO, 2013 [30] | Plasma | 16 | Up | 0.91 (0.87–0.95) |
||||
21 | Up | 0.81 (0.74–0.88) |
||||||
145 | Down | 0.63 (0.52–0.74) |
||||||
451 | Up | 0.94 (0.91–1.00) |
||||||
Si H, 2013 [31] | Serum | 21 | Up | 0.93 (0.89–0.92) |
||||
92a | Down | 0.92 (0.87–0.97) |
||||||
Wang PY, 2013 [32] | Serum | 182 | Up | |||||
Zeng RC, 2013 [33] | Plasma | 30a | Down | 0.01 | 0.76 (0.68–0.83) |
74.00 | 65.60 | |
Eichelser C, 2014 [34] | Serum | 101 | Up | |||||
372 | Up | |||||||
373 | Up | |||||||
Hamdi K, 2014 [35] | Serum | 24 | Down | |||||
320 | Down | |||||||
335 | Down | |||||||
337 | Down | |||||||
451 | Down | 15.80 | ||||||
486 | Down | |||||||
548 | Down | |||||||
15a | Down | |||||||
29a | Down | |||||||
30b | Down | |||||||
342-3p | Down | |||||||
342-5p | Down | |||||||
Joosse SA, 2014 [36] | Serum | 202 | Up | |||||
Let-7b | Up | |||||||
Kodahl AR, 2014 [37] | Serum | 107 | 0.66 | |||||
139 | 1.44 | |||||||
143 | 1.65 | |||||||
145 | 1.56 | |||||||
365 | 1.88 | |||||||
425 | 0.84 | |||||||
133a | 1.68 | |||||||
15a | 1.84 | |||||||
18a | 0.65 | |||||||
Mar-Aguilar F, 2014 [38] | Serum | 21 | 6.48 | 0.95 (0.91–0.99) |
94.40 | 80.00 | ||
145 | 15.93 | 0.98 (0.95–1.00) |
94.40 | 100.00 | ||||
155 | 7.92 | 0.99 (0.99–1.00) |
94.40 | 100.00 | ||||
191 | 4.85 | 0.79 (0.71–0.88) |
72.20 | 90.00 | ||||
382 | 0.97 (0.94–1.00) |
94.40 | 90.00 | |||||
10b | 59.22 | 0.95 (0.91–0.99) |
83.30 | 100.00 | ||||
125b | 8.46 | 0.95 (0.91–0.99) |
88.90 | 80.00 | ||||
McDermott AM, 2014 [39] | Serum | 223 | Down | |||||
652 | Down | |||||||
181a | Down | |||||||
29a | Down | |||||||
Shen J, 2014 [40] | Plasma | 409 | ||||||
133a | 8.30 | |||||||
148b | 5.10 | |||||||
Sochor M, 2014 [41] | Serum | 24 | Up | |||||
155 | Up | |||||||
181b | Up | |||||||
19a | Up | |||||||
Zearo S, 2014 [42] | Serum | 484 | 1.60 | |||||
Zhao FL, 2014 [43] | Serum | 195 | Down | 0.50 | 0.86 (0.82–0.90) |
69.00 | 89.20 | 2.38 |
Antolin S, 2015 [44] | Blood, serum and plasma | 141 | ||||||
200c | Down | 0.79 | 90.00 | 70.20 | ||||
Li XX, 2015 [45] | Serum | Let-7c | Down | 0.85 (0.79–0.91) |
87.50 | 78.90 | ||
Mangolini A (A), 2015 [46] | Serum | 145 | Down | |||||
425 | Down | |||||||
652 | Down | 0.83 (0.73–0.93) |
||||||
10b | Up | |||||||
148b | Down | 0.74 (0.62–0.86) |
||||||
Mangolini A (B), 2015 [46] | Serum | 145 | Down | |||||
425 | Down | |||||||
652 | Down | 0.69 (0.58–0.80) |
||||||
10b | Up | |||||||
148b | Down | 0.66 (0.51–0.80) |
||||||
Matamala N, 2015 [47] | Plasma | 21 | Up | 0.61 (0.53–0.68) |
||||
96 | Up | 0.72 (0.65–0.78) |
73.00 | 66.00 | ||||
505 | Up | 0.72 (0.66–0.79) |
75.00 | 60.00 | ||||
125b | Up | 0.64 (0.56–0.71) |
||||||
Shaker O, 2015 [48] | Serum | 155 | Up | 39.57 | 0.99 (0.99–1.00) |
94.10 | 100.00 | 39.57 |
197 | Up | 29.80 | 0.98 (0.95–1.00) |
95.30 | 100.00 | 29.80 | ||
205 | Up | 27.48 | 0.99 (0.98–1.00) |
98.80 | 100.00 | 27.48 | ||
29b | Up | 41.94 | 0.99 (0.98–1.00) |
98.80 | 100.00 | 41.94 | ||
Zhang L, 2015 [49] | Serum | 424 | Up | 0.75 (0.67–0.84) |
1.77 | |||
199a | Up | 0.92 (0.87–0.96) |
2.65 | |||||
29c | Up | 0.72 (0.64–0.81) |
1.97 | |||||
Frères P, 2016 [50] | Plasma | 16 | 1.70 | |||||
22 | 1.00 | |||||||
103 | 0.80 | |||||||
107 | 0.80 | |||||||
148a | 1.40 | |||||||
19b | 1.20 | |||||||
Let-7d | 0.90 | |||||||
Let-7i | 0.70 | |||||||
Fu L, 2016 [51] | Serum | 184 | Down | 0.48 | 0.74 (0.66–0.82) |
87.50 | 71.00 | |
382 | Up | 1.32 | 0.90 (0.85–0.96) |
93.00 | 75.00 | |||
598 | Down | 1.61 | 0.74 (0.66–0.82) |
52.00 | 92.50 | |||
1246 | Up | 0.55 | 0.94 (0.90–0.98) |
95.00 | 85.00 | |||
Hamam R, 2016 [52] | Serum and Plasma | 188 | Up | |||||
1202 | Up | |||||||
1207 | Up | |||||||
1225 | Up | |||||||
1290 | Up | |||||||
3141 | Up | |||||||
4270 | Up | |||||||
4281 | Up | |||||||
642b | Up | |||||||
Hannafon BN, 2016 [53] | Plasma | 21 | Up | 0.69 (0.49–0.89) |
||||
122 | Up | |||||||
1246 | Up | 0.69 (0.50–0.88) |
||||||
Let-7a | Up | |||||||
Motawi TM, 2016 [54] | Serum | 21 | 1.14 | 0.98 (0.96–1.00) |
96.00 | 94.00 | 2.20 | |
221 | 1.21 | 0.97 (0.94–1.00) |
92.00 | 88.00 | 2.09 | |||
Shimomura A, 2016 [55] | Serum | 1246 | 88.30 | 93.40 | ||||
1307 | 100.00 | 53.10 | ||||||
4634 | 3.40 | 73.60 | ||||||
6861 | 99.80 | 79.40 | ||||||
6875 | 14.70 | 76.80 | ||||||
Thakur S, 2016 [56] | Serum | 21 | Up | 0.79 (0.71–0.86) |
88.00 | 65.00 | ||
145 | Down | 0.73 (0.66–0.81) |
74.00 | 56.00 | ||||
195 | Down | 0.80 (0.74–0.87) |
77.00 | 71.00 | ||||
210 | 0.64 (0.55–0.72) |
78.00 | 61.00 | |||||
221 | 0.63 (0.54–0.71) |
65.00 | 57.00 | |||||
Let-7a | 0.76 (0.69–0.83) |
71.00 | 67.00 | |||||
Gao S, 2017 [57] | Plasma | 155 | Up | 0.77 (0.68–0.86) |
||||
Zhang K, 2017 [58] | Blood | 96 | Up | 2.73 | 0.77 | 53.00 | 100.00 | |
182 | Up | 1.01 | 0.76 | 53.00 | 92.00 | |||
942 | Up | 1.04 | 0.81 | 67.00 | 100.00 | |||
30b | Up | 2.04 | 0.93 | 80.00 | 100.00 | |||
374b | Up | 1.52 | 0.82 | 87.00 | 69.00 | |||
Heydari N, 2018 [59] | Serum | 140 | Up | 0.13 | 0.67 (0.55–0.79) |
70.00 | 50.00 | |
Zaleski M, 2018 [60] | Plasma | 21 | 0.58 (0.46–0.71) |
|||||
92 | 0.46 (0.33–0.60) |
|||||||
155 | 0.53 (0.36–0.69) |
|||||||
222 | 0.53 (0.40–0.67) |
|||||||
34a | 0.72 (0.61–0.84) |
|||||||
Let-7c | 0.51 (0.38–0.64) |
|||||||
Kaharam M, 2019 [61] | Blood | 101-3p | ||||||
126-3p | ||||||||
126-5p | ||||||||
144-3p | ||||||||
144-5p | ||||||||
301a | ||||||||
664b | ||||||||
McAnena P, 2019 [62] | Blood | 195 | 0.73 | |||||
331 | 2.94 | |||||||
181a | 1.19 | |||||||
Peña-Cano MI, 2019 [63] | Serum | 17 | Up | 0.50 | ||||
195 | Up | 0.04 | 0.88 (0.78–0.98) |
83.30 | 78.30 | 4.33 | ||
221 | Down | 0.70 | ||||||
Raheem AR, 2019 [64] | Serum | 34a | Down | 5.05 | 0.67 (0.53–0.81) |
60.00 | 63.00 | |
Soleimanpour E, 2019 [65] | Plasma | 21 | Up | 0.92 | ||||
155 | Up | 0.99 | ||||||
Anwar SL, 2020 [66] | Plasma | 155 | Up | |||||
Arabkari V, 2020 [67] | Blood | 16 | Up | 0.61 (0.47–0.76) |
||||
21 | Up | 0.65 (0.51–0.79) |
1.35 | |||||
145 | Up | 0.83 (0.72–0.94) |
1.61 | |||||
155 | Up | 0.76 (0.66–0.89) |
1.63 | |||||
195 | Down | 0.81 (0.69–0.92) |
0.14 | |||||
486 | Up | 0.90 (0.81–0.97) |
2.25 | |||||
181a | 1.52 | |||||||
451a | Up | 0.73 (0.61–0.86) |
1.62 | |||||
Ashirbekov Y, 2020 [68] | Plasma | 16 | 0.69 | |||||
21 | 1.35 | |||||||
29 | 0.98 | |||||||
145 | 2.36 | |||||||
191 | 1.87 | |||||||
210 | 0.69 | |||||||
222 | 0.98 | |||||||
Guo H, 2020 [69] | Plasma | 21 | 0.66 (0.53–0.78) |
|||||
1273g | 0.63 (0.51–0.76) |
|||||||
Holubekova V, 2020 [70] | Plasma | 484 | Up | 1.10 | ||||
1260a | Up | 1.22 | ||||||
130a | Up | 1.20 | ||||||
99a | Up | 1.33 | ||||||
Hosseini Mojahed FH, 2020 [71] | Serum | 155 | Up | 1.40 | 0.89 | 77.80 | 88.89 | 1.00 |
Ibrahim AM, 2020 [72] | Plasma | 21 | 4.94 | 0.78 | 63.30 | 100.00 | ||
145 | 0.78 | 0.70 | 45.00 | 83.30 | ||||
10b | 2.52 | 0.73 | 53.30 | 100.00 | ||||
181a | 1.51 | 0.70 | 50.00 | 80.00 | ||||
Let-7 | 0.52 | 0.72 | 50.00 | 93.30 | ||||
Jang JY, 2020 [73] | Plasma | 21 | Down | 0.92 | ||||
24 | Down | 0.96 | 65.00 | 96.00 | ||||
202 | Down | 0.86 | ||||||
206 | Down | 0.94 | 79.00 | 96.00 | ||||
223 | Down | 0.81 | ||||||
373 | Down | 0.96 | ||||||
1246 | Down | 0.93 | 53.00 | 95.00 | ||||
6875 | Down | 0.96 | 86.00 | 96.00 | ||||
219b | Down | 0.88 | ||||||
Kim J, 2020 [74] | Plasma | 202 | Up | 2.10 | 0.95 (0.88–1.02) |
90.00 | 93.30 | 9.60 |
Pastor-Navarro B, 2020 [75] | Serum | 21 | 0.77 (0.68–0.87) |
|||||
155 | 0.32 (0.68–0.87) |
|||||||
205 | 0.65 (0.68–0.87) |
|||||||
Bakr NM, 2021 [76] | Blood | 373 | 360.00 | 0.98 (0.95–0.99) |
90.80 | 98.40 | ||
Diansyah MN, 2021 [77] | Plasma | 21 | 1.66 | 0.92 (0.83–1) |
92.30 | 81.20 | 4.36 | |
Itani MM, 2021 [78] | Plasma | 21 | Up | 4.46 | 0.76 (0.64–0.88) |
73.00 | 81.00 | |
139 | Up | 11.69 | 0.74 (0.62–0.87) |
78.00 | 75.00 | |||
145 | Up | 10.18 | 0.78 (0.66–0.90) |
83.00 | 78.00 | |||
155 | Up | 8.54 | 0.83 (0.71–0.95) |
76.00 | 96.00 | |||
425 | Up | 9.09 | 0.81 (0.69–0.93) |
78.00 | 91.00 | |||
451 | Down | 10.54 | 0.70 (0.57–0.83) |
78.00 | 75.00 | |||
130a | Up | 7.96 | 0.83 (0.72–0.94) |
70.00 | 100.00 | |||
23a | Up | 2.50 | 0.73 (0.61–0.85) |
73.00 | 72.00 | |||
Mohmmed EA, 2021 [79] | Serum and Plasma | 106a | Up | 0.95 | 83.00 | 100.00 | 3.63 | |
Nashtahosseini Z, 2021 [80] | Serum | 210 | Up | 0.82 | 0.72 (0.60–0.83) |
68.00 | 51.00 | 2.72 |
660 | Up | 0.77 | 0.77 (0.66–0.88) |
79.00 | 61.00 | 2.71 | ||
Zhang K, 2021 [81] | Blood | 185 | Up | 1.08 | 0.91 (0.83–0.99) |
91.18 | 76.92 | 4.00 |
362 | Up | 1.53 | 0.93 (0.88–0.99) |
83.82 | 100.00 | 2.97 | ||
106b | Up | 1.26 | 0.82 (0.68–0.95) |
79.41 | 76.92 | 1.89 | ||
142-3p | Up | 6.87 | 0.85 (0.76–0.98) |
97.06 | 61.54 | 3.18 | ||
142-5p | Up | 1.60 | 0.85 (0.71–0.99) |
85.29 | 76.92 | 2.46 | ||
26b | Up | 1.34 | 0.89 (0.81–0.97) |
83.82 | 84.62 | 3.32 | ||
Zhao T, 2021 [82] | Serum | 25 | Up | 0.75 (0.66–0.84) |
57.10 | 95.00 | ||
Li X, 2022 [83] | Serum | 9 | Up | |||||
17 | ||||||||
148a | Up | |||||||
Liu H, 2022 [84] | Serum | 103a | Up | 3.40 | 0.70 (0.62–0.78) |
78.20 | 74.70 | |
Mohamed AA, 2022 [85] | Serum | 155 | Up | 7.50 | 0.94 (0.89–0.98) |
86.90 | 90.00 | |
373 | Up | 10.00 | 0.95 (0.90–0.98) |
85.00 | 100.00 | |||
10b | Up | 9.50 | 0.77 (0.69–0.84) |
60.00 | 93.00 | |||
34a | Down | 10.50 | 0.89 (0.82–0.94) |
91.00 | 75.00 | |||
Zavesky L, 2022 [86] | Plasma | 451a | Down | 1.39 | ||||
548b | Up | 3.60 | ||||||
Zou R, 2022 [87] | Serum | 24 | Up | 0.76 | 0.62 | |||
324 | Down | 0.52 | 0.31 | |||||
377 | Down | 0.73 | 0.67 | |||||
497 | Up | 0.56 | 0.15 | |||||
125b | Up | 0.58 | 0.13 | |||||
133a | Up | 0.63 | 0.41 | |||||
19b | Down | 0.63 | 0.26 | |||||
374c | Down | 0.71 | 0.99 |